Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BiomX Inc. (PHGE)

0.3434   -0.042 (-10.92%) 02-07 16:00
Open: 0.3998 Pre. Close: 0.3855
High: 0.3929 Low: 0.31
Volume: 200,554 Market Cap: 10(M)

Technical analysis

as of: 2023-02-07 4:30:56 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.51     One year: 0.59
Support: Support1: 0.27    Support2: 0.18
Resistance: Resistance1: 0.43    Resistance2: 0.51
Pivot: 0.34
Moving Average: MA(5): 0.37     MA(20): 0.32
MA(100): 0.3     MA(250): 0.74
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 65     %D(3): 72.2
RSI: RSI(14): 56.1
52-week: High: 2.14  Low: 0.13
Average Vol(K): 3-Month: 473 (K)  10-Days: 200 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PHGE ] has closed above bottom band by 50.0%. Bollinger Bands are 16.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.4 - 0.4 0.4 - 0.4
Low: 0.31 - 0.31 0.31 - 0.31
Close: 0.34 - 0.34 0.34 - 0.35

Company Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Headline News

Tue, 24 Jan 2023
Do Traders Think Biomx Inc (PHGE) Can Keep Climbing Tuesday? - InvestorsObserver

Fri, 20 Jan 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace

Fri, 23 Dec 2022
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday - Benzinga

Wed, 09 Nov 2022
BiomX Reports Third Quarter 2022 Financial Results and Provides ... - GlobeNewswire

Wed, 06 Jul 2022
BiomX Announces Voluntary Delisting from the Tel Aviv Stock ... - Business Wire

Tue, 28 Jun 2022
Boehringer Ingelheim and BiomX Collaborate to Discover ... - Business Wire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 29 (M)
Shares Float 17 (M)
% Held by Insiders 20 (%)
% Held by Institutions 24.3 (%)
Shares Short 31 (K)
Shares Short P.Month 111 (K)

Stock Financials

EPS -1.42
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.88
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -27.7
Return on Equity (ttm) -58.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.19
Qtrly Earnings Growth 0
Operating Cash Flow -26 (M)
Levered Free Cash Flow -17 (M)

Stock Valuations

PE Ratio -0.25
PEG Ratio 0
Price to Book value 0.18
Price to Sales 0
Price to Cash Flow -0.39

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.